Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:51 pm Purchase | 2024-09-30 | 13G | Trevi Therapeutics, Inc. TRVI | Venrock Healthcare Capital Partners II L.P. | 7,676,934 9.990% | 969,370 (+14.45%) | Filing History |
| 2024-11-14 5:49 pm Sale | 2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II L.P. | 1,204,094 1.800% | -4,349,458 (-78.32%) | Filing History |
| 2024-11-14 5:48 pm Purchase | 2024-09-30 | 13G | Instil Bio, Inc. TIL | Venrock Healthcare Capital Partners II L.P. | 33,177 0.500% | 33,177 (New Position) | Filing History |
| 2024-11-14 5:47 pm Purchase | 2024-09-30 | 13G | Cogent Biosciences, Inc. COGT | Venrock Healthcare Capital Partners II L.P. | 11,516,667 9.990% | 2,477,823 (+27.41%) | Filing History |
| 2024-02-14 8:56 pm Purchase | 2023-12-31 | 13G | DBV Technologies S.A. DBVT | Venrock Healthcare Capital Partners II L.P. | 482,733 9.990% | 12,559 (+2.67%) | Filing History |
| 2024-02-14 8:47 pm Purchase | 2023-12-31 | 13G | Trevi Therapeutics, Inc. TRVI | Venrock Healthcare Capital Partners II L.P. | 6,707,564 9.990% | 395,372 (+6.26%) | Filing History |
| 2024-02-14 8:46 pm Sale | 2023-12-31 | 13G | Annexon, Inc. ANNX | Venrock Healthcare Capital Partners II L.P. | 968,679 1.200% | -3,960,321 (-80.35%) | Filing History |
| 2024-02-14 8:35 pm Sale | 2023-12-31 | 13G | Savara Inc. SVRA | Venrock Healthcare Capital Partners II L.P. | 3,500,000 2.600% | -2,851,531 (-44.90%) | Filing History |
| 2024-02-14 8:35 pm Purchase | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II L.P. | 5,553,552 9.999% | 2,120,284 (+61.76%) | Filing History |
| 2024-02-14 8:34 pm Sale | 2023-12-31 | 13G | GH Research PLC GHRS | Venrock Healthcare Capital Partners II L.P. | 1,318,327 2.500% | -2,198,798 (-62.52%) | Filing History |
| 2024-02-14 8:34 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Venrock Healthcare Capital Partners II L.P. | 0 0.000% | -3,867,749 (Position Closed) | Filing History |
| 2024-02-14 8:33 pm Purchase | 2023-12-31 | 13G | Cogent Biosciences, Inc. COGT | Venrock Healthcare Capital Partners II L.P. | 9,038,844 9.990% | 1,729,716 (+23.67%) | Filing History |
| 2024-02-14 8:32 pm Sale | 2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Venrock Healthcare Capital Partners II L.P. | 0 0.000% | -4,563,962 (Position Closed) | Filing History |
| 2023-02-14 5:11 pm Sale | 2022-12-31 | 13G | Axsome Therapeutics, Inc. AXSM | Venrock Healthcare Capital Partners II L.P. | 0 0.000% | -2,333,975 (Position Closed) | Filing History |
| 2023-02-14 4:55 pm Purchase | 2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI | Venrock Healthcare Capital Partners II L.P. | 6,312,192 9.990% | 2,643,858 (+72.07%) | Filing History |
| 2023-02-14 4:55 pm Purchase | 2022-12-31 | 13G | Cogent Biosciences, Inc. COGT | Venrock Healthcare Capital Partners II L.P. | 7,309,128 9.990% | 3,007,002 (+69.90%) | Filing History |
| 2023-02-14 4:40 pm Purchase | 2022-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II L.P. | 3,433,268 9.999% | 218 (+0.01%) | Filing History |
| 2023-02-14 4:31 pm Purchase | 2022-12-31 | 13G | DBV Technologies S.A. DBVT | Venrock Healthcare Capital Partners II L.P. | 470,174 9.990% | 33 (+0.01%) | Filing History |
| 2023-02-14 4:13 pm Sale | 2022-12-31 | 13G | LianBio LIANY | Venrock Healthcare Capital Partners II L.P. | 4,793,047 4.400% | -585,294 (-10.88%) | Filing History |
| 2023-02-14 4:09 pm Sale | 2022-12-31 | 13G | Inozyme Pharma, Inc. INZY | Venrock Healthcare Capital Partners II L.P. | 3,867,749 9.300% | -197,251 (-4.85%) | Filing History |